A former Pfizer manufacturing facility in Indiana, US, looks set for a new lease of life after technology company NantWorks …
Once predicted to be a blockbuster, inhaled insulin product Exubera is to be abandoned by Pfizer because of poor sales.Exubera …
Diabetes patients who are genuinely needle-phobic will be among the few to be given Pfizer’s inhaled insulin product Exubera on …
Pfizer has paid $1.3 billion to buy out its marketing partner’s stake in new inhaled diabetes drug Exubera.The US company …
NIHR chief scientific adviser visits Huddersfield health innovation campus
One in three UK women with migraine say symptoms taken less seriously
Report highlights scope to expand day surgery
Sygnature formalises drug discovery collaboration with X-Chem
Codis appoints Steven Facer as chief commercial officer


